相关实验视频
Updated: May 12, 2026
06:53
Cell Population Analyses During Skin Carcinogenesis
Published on: August 21, 2013
12.4K
在先进的基底细胞癌中使用vismodegib和sonidegib的现实世界经验:一项多中心意大利研究
Mario Valenti1, Sara Di Giulio2, Andrea Carugno3
1Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan. mario.valenti@hunimed.eu.
Dermatology reports
|February 18, 2025
概括
这项研究比较了意大利高级基底细胞癌的vismodegib和sonidegib. 在现实世界中使用时,sonidegib显示出更高的响应率和较少的不良事件,而不是vismodegib.
科学领域:
- 在瘤学瘤学.
- 皮肤病学 皮肤病学
背景情况:
- 维斯莫迪吉布和索尼迪吉布是FDA批准的平滑 (SMO) 抑制剂,用于晚期基底细胞癌 (aBCC).
- 在aBCC中关于SMO抑制剂有效性和安全性的真实数据对于临床决策至关重要.
研究的目的:
- 评估vismodegib和sonidegib在晚期基底细胞癌 (aBCC) 患者的实际有效性和安全性.
- 为了比较vismodegib和sonidegib之间的治疗结果,包括反应率,持续时间和不良事件.
主要方法:
- 一项回顾性,观察性,多中心研究分析了57名局部晚期基底细胞癌 (laBCC) 患者的医疗记录,这些患者接受了SMO抑制剂治疗.
- 患者在2019年7月至2024年4月期间接受了临床试验之外的vismodegib (n=19) 或sonidegib (n=38).
主要成果:
- 与维斯莫迪吉布 (CR 31.6%,PR 26.3%) 相比,索尼迪吉布的整体响应率更高 (CR 47.4%,PR 36.8%).
- 索尼迪基布的中位治疗持续时间更长 (12个月与8个月相比),因不良事件而导致的治疗中断较少 (13.2%与47.4%相比).
- 使用sonidegib (7.9%) 的病变进展率低于使用vismodegib (26.3%).
结论:
- 在现实意大利环境中,sonidegib似乎是一种更有效,更好地耐受SMO抑制剂,用于晚期基底细胞癌.
- 这些发现支持sonidegib作为先进的基底细胞癌患者的有价值的治疗选择,与vismodegib相比,提供更好的结果和耐受性.
相关概念视频
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:19Clinical Applications of Epidermal Stem Cells
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own EpiSCs...